Background: The incidence of small intestine neuroendocrine tumors (SI-NETs) is increasing, but few studies have investigated risk factors for their occurrence, suggesting that family history (FH) of any cancer, smoking and previous cholecystectomy are associated with an increased risk. Such studies investigated small series or examined cancer registries without direct interviews. Aim: We therefore aimed at clarifying risk and protective factors for the occurrence of sporadic SI-NETs. Subjects and Methods: We performed a multicenter case-control study. Patients with a histologic diagnosis of SI-NETs were prospectively evaluated, excluding familial syndromes. Controls with non-neoplastic/non-chronic disorders seen at gastrointestinal outpatients clinics were matched for sex and age (4:1). All subjects were directly interviewed by means of a specific questionnaire on potential risk and protective factors. Cases and controls were compared by Fisher's test or Student's t test for categorical or continuous variables. Explanatory variables were analyzed by simple logistic regression analysis. A multiple logistic regression analysis was performed with an Enter model; p < 0.05 was considered significant. Results: 215 SI-NET patients and 860 controls were enrolled. FH of colorectal cancer (CRC) (8.8 vs. 5.0%) and breast cancer (10.2 vs. 4.8%), heavy smoking (24.7 vs. 14.8%) and drinking >21 alcohol units per week (7.4 vs. 3.8%) were all significantly more frequent in SI-NET patients than in controls. Multivariate analysis showed that FH of CRC (OR 2.23, 95% CI 1.29-3.84, p = 0.003), FH of breast cancer (OR 2.05, 95% CI 1.13-3.69, p = 0.01) and smoking (OR 1.47, 95% CI 1.07-2.03, p = 0.01) and in particular heavy smoking (OR 1.94, 95% CI 1.29-3.84, p = 0.0008) were associated with an increased risk for carcinoid occurrence, while use of aspirin can be considered a protective factor (OR 0.20, 95% CI 0.06-0.65, p = 0.008). Conclusion: FH of colorectal and breast cancer as well as smoking seem to be risk factors for the development of SI-NETs, while use of aspirin might be a protective factor. These factors partially overlap with those associated with CRC, but are different from those previously associated with pancreatic neuroendocrine tumors. These findings may suggest that the mechanisms of carcinogenesis for endocrine cells in different sites can be specific and similar to those of their exocrine counterparts.

Keywords:
Small intestine neuroendocrine tumors, Risk factors, Smoking, Family history, Aspirin
1.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.
2.
Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B: TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-762.
3.
Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, Arnold R, Denecke T, Plöckinger U, Salazar R, Grossman A; Barcelona Consensus Conference participants: ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012;95:135-156.
4.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after carcinoids: epidemiology of and prognostic factors for neuroendocrine tumours in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
5.
Bosman FT, Carneiro F, Hruban RH, Theise ND: WHO Classification of Tumours of the Digestive System. Lyon, IARC Press, 2010.
6.
Ellis L, Shale MJ, Coleman MP: Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1972. Am J Gastroenterol 2010;105:2563-2569.
7.
Panzuto F, Campana D, Fazio N, Brizzi MP, Bonisegna L, Nori F, Di Meglio G, Capurso G, Scarpa A, Dogliotti L, De Braud F, Tomassetti P, Delle Fave G, Falconi M: Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. Neuroendocrinology 2012;96:32-40.
8.
Modlin IM, Gustafsson BI, Pavel M, Svejda B, Lawrence B, Kidd M: A nomogram to assess small-intestinal neuroendocrine tumor (‘carcinoid') survival. Neuroendocrinology 2010;92:143-157.
9.
Babovic-Vuksanovic D, Constantinou CL, Rubin J, Rowland CM, Schaid DJ, Karmes PS: Familial occurrence of carcinoid tumors and association with other malignant neoplasms. Cancer Epidemiol Biomarkers Prev 1999;8:715-719.
10.
Hemminki K, Li X: Familial carcinoid tumors and subsequent cancer: a nation-wide epidemiologic study from Sweden. Int J Cancer 2001;94:444-448.
11.
Kharazmi E, Pukkala E, Sundquist K, Hemminki K: Familial risk of small intestinal carcinoid and adenocarcinoma. Clin Gastroenterol Hepatol 2013;11:944-949.
12.
Duerr EM, Chung DC: Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 2007;21:1-14.
13.
Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC: Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev 2008;17:959-965.
14.
Capurso G, Falconi M, Panzuto F, Rinzivillo M, Boninsegna L, Bettini R, Corleto V, Borgia P, Pederzoli P, Scarpa A, Delle Fave G: Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients. Am J Gastroenterol 2009;104:3034-3041.
15.
Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC: Risk factors associated with neuroendocrine tumors: a US-based case-control study. Int J Cancer 2008;123:867-873.
16.
Kaerlev L, Teglbjaerg PS, Sabroe S, Kolstad HA, Ahrens W, Eriksson M, Guénel P, Gorini G, Hardell L, Cyr D, Zambon P, Stang A, Olsen J: The importance of smoking and medical history for development of small bowel carcinoid tumor: a European population-based case-control study. Cancer Causes Control 2002;13:27-34.
17.
Kaerlev l, Teglbjaerg PS, Sabroe S, Kolstad HA, Ahrens W, Eriksson M, Guénel P, Hardell L, Launoy G, Merler E, Merletti F, Stang A, Olsen J: Is there an association between alcohol intake or smoking and small bowel adenocarcinoma? Results from an European multi-center case-control study. Cancer Causes Control 2000;11:791-797.
18.
Chen CC, Neugut AI, Rotterdam H: Risk factors for adenocarcinomas and malignant carcinoids of the small intestine: preliminary findings. Cancer Epidemiol Biomarkers Prev 1994;3:205-207.
19.
Lagergren J, Ye W, Ekbom A: Intestinal cancer after cholecystectomy: is bile involved in carcinogenesis? Gastroenterology 2001;121:542-547.
20.
West NE, Wise PE, Herline AJ, Muldoon RL, Chopp WV, Schwartz DA: Carcinoid tumors are 15 times more common in patients with Crohn's disease. Inflamm Bowel Dis 2007;13:1129-1134.
21.
Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS: Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005;294:914-923.
22.
Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF Jr, Blot WJ: Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
23.
Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S: Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000;9:119-123.
24.
Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH: Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 2008;52:1141-1147.
25.
Capurso G, Boccia S, Salvia R, Del Chiaro M, Frulloni L, Arcidiacono PG, Zerbi A, Manta R, Fabbri C, Ventrucci M, Tarantino I, Piciucchi M, Carnuccio A, Boggi U, Leoncini E, Costamagna G, Delle Fave G, Pezzilli R, Bassi C, Larghi A; Italian Association for Study of Pancreas (AISP); Intraductal Papillary Mucinous Neoplasm (IPMN) Study Group: Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a multicentre case-control study. Am J Gastroenterol 2013;108:1003-1009.
26.
Wang H, Yang L, Zou L, Huang D, Guo Y, Pan M, Tan Y, Zhong H, Ji W, Ran P, Zhong N, Lu J: Association between chronic obstructive pulmonary disease and lung cancer: a case-control study in Southern Chinese and a meta-analysis. PLoS One 2012;7:e46144.
27.
Corrao G, Bagnardi V, Zambon A, La Vecchia C: A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004;38:613-619.
28.
Loguercio C, Federico A, Bianchi C, D'Auria M, Tallarico A, Bianco M, Fiorito R, Del Vecchio Blanco C, Stroffolini T: Drinking habits and risk of altered liver enzymes in the general population of a rural area in Southern Italy. Dig Liver Dis 2007;39:748-752.
29.
Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-268.
30.
Chow WH, Linet MS, McLaughlin JK, Hsing AW, Chien HT, Blot WJ: Risk factors for small intestine cancer. Cancer Causes Control 1993;4:163-169.
31.
Weiss NS, Yang CT: Incidence of histologic types of cancer of the small intestine. J Natl Cancer Inst 1987;78:653-656.
32.
Kamp K, Damhuis RA, Feelders RA, de Herder WW: Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas. Endocr Relat Cancer 2012;19:95-99.
33.
Jang JH, Cotterchio M, Gallinger S, Knight JA, Daftary D: Family history of hormonal cancers and colorectal cancer risk: a case-control study conducted in Ontario. Int J Cancer 2009;125:918-925.
34.
Rokavec M, Justenhoven C, Schroth W, Istrate MA, Haas S, Fischer HP, Vollmert C, Illig T, Hamann U, Ko YD, Glavac D, Brauch H: A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk. Clin Cancer Res 2007;15:7506-7514.
35.
Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J: A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death Dis 2013;4:e492.
36.
Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D: Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012;35:2402-2411.
37.
Van Rees BP, Ristimaki A: Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract. Scand J Gastroenterol 2001;36:897-903.
38.
Mizuno S, Kato K, Hashimoto A, Sugitani M, Sheikh A, Komuro S, Jike T, Iwasaki A, Arakawa Y, Nemoto N: Expression of cyclo-oxygenase-2 in gastrointestinal carcinoid tumors. J Gastroenterol Hepatol 2006;21:1313-1319.
39.
Bergmann F, Breinig M, Höpfner M, Rieker RJ, Fischer L, Köhler C, Esposito I, Kleeff J, Herpel E, Ehemann V, Friess H, Schirmacher P, Kern MA: Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am J Gastroenterol 2009;104:171-181.
40.
Bravi F, Bosetti C, Negri E, Lagiou P, La Vecchia C: Family history of cancer provided by hospital controls was satisfactorily reliable. J Clin Epidemiol 2007;60:171-175.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.